3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
15
Urinary Bladder Neoplasms
11
Prostatic Neoplasms
9
Carcinoma, Transitional Cell
6
Non-Muscle Invasive Bladder Neoplasms
4
Urothelial Cancer
3
Urologic Neoplasms
3
Ureteral Neoplasms
3
Sarcoma
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Melanoma
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Urethral Neoplasms
2
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neuroblastoma
2
Neoplasms
2
Metastatic Castration-resistant Prostate Cancer
2
Medulloblastoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Prostate Cancer Non-Metastatic
×
Genitourinary
×
Clear all
NCT02200614
2022-06-28
ARAMIS
Bayer
Phase 3
Completed
1,509 enrolled
13 charts
1 FDA